Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis

Lancet

Volumn 348, Issue 9043, 1996, Pages 1677-1681

  Merkel, C ^a   Marin, R ^b   Enzo, E ^b   Donada, C ^b   Cavallarin, G ^b   Torboli, P ^b   Amodio, P ^b   Sebastianelli, G ^b   Sacerdoti, D ^b   Felder, M ^b   Mazzaro, C ^b   Beltrame, P ^b   Gatta, A ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE MONONITRATE; NADOLOL;

ADULT; ARTICLE; ASTHMA; ATRIOVENTRICULAR BLOCK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGUS VARICES BLEEDING; FEMALE; FOLLOW UP; HEADACHE; HEART FAILURE; HUMAN; HYPOTENSION; IMPOTENCE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NIGHTMARE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VERTIGO;

EID: 0030597496     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)05406-2     Document Type: Article

References (22)

1. 1 Graham DY, Smith JL. The course of patients after variceal haemorrhage. Gastroenterology 1981; 80: 800-09.
2. 2 Schlichting P, Christensen E, Fauerholdt L, et al. Main causes of death in cirrhosis. Scand J Gastroenterol 1983; 18: 881-88.
3. 3 Poynard T, Calés P, Pasta L, et al. β-adrenergic-antagonists in the prevention of first gastrointestinal bleeding in patients with cirrhosis and oesophageal varices: an analysis of data and prognostic factors in 589 patients from four randomised clinical trials. N Engl J Med 1991; 324: 1532-38.
4. 4 Pagliaro L, D'Amico G, Soerensen TIA, et al. Prevention of first bleeding in cirrhosis: a meta-analysis of randomized clinical trials of nonsurgical treatment. Ann Intern Med 1992; 117: 59-70.
5. 5 D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332-54.
6. 6 Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of first bleeding. Gastroenterology 1990; 99: 1401-07.
7. 7 Sacerdoti D, Merkel C, Gatta A. Importance of the 1-month-effect of nadodol on portal pressure in predicting failure of rebleeding in cirrhosis. J Hepatol 1991; 12: 124-25.
8. 8 Feu F, Garcia-Pagan JC, Bosch J, et al. Relation between portal pressure reponse to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056-59.
9. 9 Garcia-Pagan JC, Navasa M, Bosch J, Bru C, Pizcueta P, Rodés J. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology 1990; 11: 230-38.
10. 10 Vorobioff J, Picabea E, Gamen G, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal hypertensive patients: long-term hemodynamic and renal effects. Hepatology 1993; 18: 477-84.
11. 11 Garcia-Pagan JC, Feu F, Bosch J, Rodés J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: a randomized controlled study. Ann Intern Med 1991; 114: 869-73.
12. 12 Merkel C, Gatta A, Donada C, et al. Long-term effect of nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. Hepatology 1995; 22: 808-13.
13. 13 Beppu K, Inokuchi K, Koyanagy N, et al. Prediction of variceal haemorrhage by oesophageal endoscopy. Gastrointest Edosc 1981; 27: 213-18.
14. 14 Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-64.
15. 15 Jaeschke R, Oxman A, Guyatt G. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis. Am J Med 1990; 88: 279-86.
16. 16 North Italian Endoscopic Club for the Study and Treatment of Oesophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and oesophageal varices. N Engl J Med 1988; 319: 983-89.
17. 17 Abshagen U, Betzien G, Endele R, Kaufmann B. Pharmacokinetics of intravenous and oral isosorbide-5-mononitrate. Eur J Clin Pharmacol 1981; 20: 269-75.
18. 18 Smith D, Aldrich W, Dey M, Enver R, Warner R, Weiersta HR. A pharmacokinetic model for isosorbide dinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate. Drug Metab Dispos 1990; 18: 429-34.
19. 19 Bidoggia H. Isosorbide-5-mononitrate and isorbide dinitrate retard in the treatment of coronary artery disease: a multi-centre study. Curr Med Res Opin 1987; 10: 601-11.
20. 20 Burroughs AK, D'Heygere F, McIntyre N. Pitfalls in the studies of prophylactic therapy for variceal bleeding in cirrhotics. Hepatology 1986; 6: 1407-13.
21. 21 Merkel C, Bolognesi M, Angeli P, et al. Prognostic indicators of survival in patients with cirrhosis and esophageal varices, without previous bleeding. Am J Gastroenterol 1989; 84: 717-22.
22. 22 Thandani U, Marcanda CR, Amsterdam E, et al. Lack of pharmacological tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate. Ann Intern Med 1994; 120: 353-59.